Article citationsMore>>

Kerbauy, M.N., Moraes, F.Y., Lok, B.H., Ma, J., Kerbauy, L.N., Spratt, D.E., Santos, F.P.S., Perini, G.F., Berlin, A., Chung, C., Hamerschlak, N. and Yahalom, J. (2017) Challenges and Opportunities in Primary CNS Lymphoma: A Systematic Review. Radiotherapy and Oncology, 122, 352-361.
https://doi.org/10.1016/j.radonc.2016.12.033

has been cited by the following article:

• TITLE: Epidemiology and Outcome of Primary Cerebral Lymphoma in Immunocompetent Patients: A Monocentric Study

  AUTHORS: Fatima Ezzahra Rida, Asmaa Harrach, Mouna Lamchahab, Mohammed Rachid, Nissrine Khoubila, Siham Cherkaoui, Abdellah Madani, Meryem Qachouh

  KEYWORDS: Primary Cerebral Lymphoma (PCL), Retrospective Study, Management

  JOURNAL NAME: Open Journal of Modern Neurosurgery, Vol.12 No.3, July 28, 2022

  ABSTRACT: Primary cerebral lymphoma (PCL) is a form of extranodal non-Hodgkin’s lymphoma with a poor prognosis. Very few cohorts have been reported in the literature. It is a rare form in 1% of extranodal lymphomas, and 3%to 4% of brain tumors. The most common histological type is diffuse large B-cell lymphoma. Survival is improved by combining immunotherapy with chemotherapy. This is a descriptive retrospective study conducted at the Casablanca hematology center over a period of 9 years. The aim of this study was to report our experience by studying the clinical, paraclinical, therapeutic and evolutionary profile of patients with primary cerebral lymphoma. We present a study of 22 patients with PCL. The clinical, radiological and histological findings are shown along with the results of treatment. Patients were aged 25-75 years (mean 47 years) with a male predominance (77%). Computed tomography (CT) scans were performed on 16 patients (73%) and Brain magnetic resonance imaging for 16 patients (73%). Typically, lesions were multiple, isodense, and showed uniform enhancement with contrast medium. Immunocytochemical studies demonstrated 21 B-cell and 1 mantle-cell lymphomas. All patients received chemotherapy through high-dose MTX with whole brain radiotherapy (WBRT). After a median follow-up of 19 months, 54% are in complete remission, 32% have died, and 14% are lost to follow-up. Overall survival at 24 months and 36 months were 72% and 52%. The event-free survival at 24 months and 36 months were 60% and 48%. This study was to investigate the clinical features of PCNSL, and evaluate the efficacy of high-dose methotrexate (MTX)-based chemotherapy for immunocompetent Moroccan patients with PCNSL.